Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DTWN | ISIN: US82711P2011 | Ticker-Symbol:
NASDAQ
08.08.25 | 21:55
0,694 US-Dollar
+10,81 % +0,068
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SILO PHARMA INC Chart 1 Jahr
5-Tage-Chart
SILO PHARMA INC 5-Tage-Chart

Aktuelle News zur SILO PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSilo Pharma, Inc.: Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform164Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), today announced the launch...
► Artikel lesen
29.07.Silo Pharma, Inc. - 8-K, Current Report1
16.07.Silo Pharma completes dosing in FDA-requested safety study for PTSD drug2
SILO PHARMA Aktie jetzt für 0€ handeln
16.07.Silo Pharma, Inc.: Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15158SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...
► Artikel lesen
10.07.Silo Pharma, Inc. - 8-K, Current Report1
07.07.Silo Pharma expects SPC-15 PTSD drug preclinical data within 90 days1
07.07.Silo Pharma, Inc.: Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025437Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market...
► Artikel lesen
03.07.Silo Pharma erhält Nasdaq-Mitteilung über Nichteinhaltung des Mindestangebotspreises1
03.07.Silo Pharma, Inc. - 8-K, Current Report1
25.06.Silo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment1
25.06.Hoth Therapeutics, Inc: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market330NEW YORK, June 25, 2025 - (ACN Newswire) - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...
► Artikel lesen
25.06.Silo Pharma to form JV with Hoth Therapeutics for obesity treatment1
25.06.Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment2
25.06.Hoth Therapeutics, Silo Pharma Launch JV To Commercialize VA-Invented Obesity Drug-
25.06.Silo Pharma, Inc.: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market160Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental...
► Artikel lesen
11.06.Silo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears454SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...
► Artikel lesen
05.06.Silo Pharma stock surges on Bitcoin reserve move1
05.06.Silo Pharma allocates $1 million to Bitcoin holdings1
05.06.Silo Pharma, Inc.: Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset284SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...
► Artikel lesen
21.05.Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug1
Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1